Literature DB >> 17202590

Chemotherapy-induced diarrhea is associated with changes in the luminal environment in the DA rat.

Andrea M Stringer1, Rachel J Gibson, Richard M Logan, Joanne M Bowen, Ann S-J Yeoh, Jaimi Burns, Dorothy M K Keefe.   

Abstract

The microflora of the gastrointestinal tract (GIT) are a complex ecosystem, performing a number of beneficial functions. Irinotecan causes both early and late diarrhea, the latter possibly caused, in part, by changes in the microflora of the GIT. Female DA rats were given atropine subcutaneously, prior to a single 200 mg/kg intraperitoneal dose of irinotecan. Animals were monitored for diarrhea and killed at 30 and 60 mins, 2, 6, 12, 24, 48, and 72 hrs after chemotherapy administration. Control rats received no treatment. Fecal samples and stomach, jejunum, and colon samples were collected and stored at -70 degrees C until required. Standard microbiological culture techniques were used to grow and isolate the flora. Biochemical tests were used to identify the bacteria. The level of growth was noted for relative comparison between time points and graded accordingly. Early diarrhea was observed in the rats from 2-6 hrs after treatment, after which time the diarrhea resolved. Late onset diarrhea was apparent 72 hrs after treatment. Changes were seen in the flora of the stomach, jejunum, colon and feces. The majority of microflora changes were seen 6, 12, and 24 hrs after treatment, with a relative increase or decrease in the presence of bacteria in comparison with control rats. In some rats bacteria were not observed at all time points, and different bacteria not seen in control animals were identified in rats treated with irinotecan. These changes were observed up to 72 hrs after treatment. In conclusion, irinotecan treatment causes changes in the flora of the stomach, jejunum, colon, and feces of rats and is associated with the development of diarrhea. These changes in flora may have systemic effects and in particular may contribute to the development of chemotherapy-induced mucositis.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17202590

Source DB:  PubMed          Journal:  Exp Biol Med (Maywood)        ISSN: 1535-3699


  24 in total

1.  Beneficial effects of cathepsin inhibition to prevent chemotherapy-induced intestinal mucositis.

Authors:  I Alamir; N Boukhettala; M Aziz; D Breuillé; P Déchelotte; M Coëffier
Journal:  Clin Exp Immunol       Date:  2010-08-20       Impact factor: 4.330

2.  Irinotecan disrupts tight junction proteins within the gut : implications for chemotherapy-induced gut toxicity.

Authors:  Hannah R Wardill; Joanne M Bowen; Noor Al-Dasooqi; Masooma Sultani; Emma Bateman; Romany Stansborough; Joseph Shirren; Rachel J Gibson
Journal:  Cancer Biol Ther       Date:  2013-12-06       Impact factor: 4.742

3.  Irinotecan-induced alterations in intestinal cell kinetics and extracellular matrix component expression in the Dark Agouti rat.

Authors:  Noor Al-Dasooqi; Joanne M Bowen; Rachel J Gibson; Richard M Logan; Andrea M Stringer; Dorothy M Keefe
Journal:  Int J Exp Pathol       Date:  2011-04-05       Impact factor: 1.925

4.  Chemotherapy-induced diarrhea: pathophysiology, frequency and guideline-based management.

Authors:  Alexander Stein; Wieland Voigt; Karin Jordan
Journal:  Ther Adv Med Oncol       Date:  2010-01       Impact factor: 8.168

Review 5.  Management of Mucositis During Chemotherapy: From Pathophysiology to Pragmatic Therapeutics.

Authors:  Ysabella Z A Van Sebille; Romany Stansborough; Hannah R Wardill; Emma Bateman; Rachel J Gibson; Dorothy M Keefe
Journal:  Curr Oncol Rep       Date:  2015-11       Impact factor: 5.075

6.  Irinotecan-induced mucositis manifesting as diarrhoea corresponds with an amended intestinal flora and mucin profile.

Authors:  Andrea M Stringer; Rachel J Gibson; Joanne M Bowen; Richard M Logan; Kimberly Ashton; Ann S J Yeoh; Noor Al-Dasooqi; Dorothy M K Keefe
Journal:  Int J Exp Pathol       Date:  2009-10       Impact factor: 1.925

Review 7.  Emerging evidence on the pathobiology of mucositis.

Authors:  Noor Al-Dasooqi; Stephen T Sonis; Joanne M Bowen; Emma Bateman; Nicole Blijlevens; Rachel J Gibson; Richard M Logan; Raj G Nair; Andrea M Stringer; Roger Yazbeck; Sharon Elad; Rajesh V Lalla
Journal:  Support Care Cancer       Date:  2013-04-21       Impact factor: 3.603

8.  Biomarkers of chemotherapy-induced diarrhoea: a clinical study of intestinal microbiome alterations, inflammation and circulating matrix metalloproteinases.

Authors:  Andrea M Stringer; Noor Al-Dasooqi; Joanne M Bowen; Thean H Tan; Maryam Radzuan; Richard M Logan; Bronwen Mayo; Dorothy M K Keefe; Rachel J Gibson
Journal:  Support Care Cancer       Date:  2013-02-10       Impact factor: 3.603

9.  A phase II, randomized, double blind trial of calcium aluminosilicate clay versus placebo for the prevention of diarrhea in patients with metastatic colorectal cancer treated with irinotecan.

Authors:  Bryan K Kee; Jeffrey S Morris; Rebecca S Slack; Todd Crocenzi; Lucas Wong; Ben Esparaz; Michael Overman; Katrina Glover; Desiree Jones; Sijin Wen; Michael J Fisch
Journal:  Support Care Cancer       Date:  2014-08-27       Impact factor: 3.603

10.  A diet containing whey protein, glutamine, and TGFbeta modulates gut protein metabolism during chemotherapy-induced mucositis in rats.

Authors:  Nabile Boukhettala; Ayman Ibrahim; Sophie Claeyssens; Magali Faure; Florence Le Pessot; Jacques Vuichoud; Alain Lavoinne; Denis Breuillé; Pierre Déchelotte; Moïse Coëffier
Journal:  Dig Dis Sci       Date:  2009-11-13       Impact factor: 3.199

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.